Contact

Oncology Authority serves as a reference resource covering cancer biology, diagnosis, treatment modalities, and survivorship across the full scope of oncologic medicine in the United States. This page describes how to direct inquiries to the appropriate channel, what geographic and subject boundaries the resource covers, what information to include in a message for efficient handling, and what response timelines are realistic. Understanding these parameters reduces friction and helps ensure that substantive questions receive substantive treatment.

How to reach this office

Inquiries directed to Oncology Authority should be submitted through the contact form hosted on this domain. The form routes messages by topic category — editorial questions, factual corrections, source disputes, and accessibility concerns are each handled through separate review queues. This separation reflects a content governance principle aligned with standards maintained by the National Cancer Institute (NCI), which distinguishes between editorial oversight, scientific accuracy review, and patient-communication functions as discrete operational responsibilities.

For factual corrections or disputed citations, the message should reference the specific page URL and the exact passage in question. This mirrors the correction-request protocol described in the International Committee of Medical Journal Editors (ICMJE) guidelines for post-publication amendment, which require that corrections be traceable to a specific statement rather than a general subject area.

Accessibility-related inquiries — including requests for content in alternative formats — should reference Section 508 of the Rehabilitation Act (29 U.S.C. § 794d), which governs electronic and information technology accessibility for federal and federally funded resources. While Oncology Authority is not a federal entity, its editorial standard is to maintain accessibility parity with federal health communication guidelines published by the U.S. Department of Health and Human Services (HHS).

Service area covered

Oncology Authority covers oncology subject matter at a national scope within the United States. Content on this resource is calibrated to U.S. regulatory frameworks, U.S. clinical practice guidelines, and U.S.-based institutional standards. The 3 primary reference bodies whose frameworks appear across this resource are:

1. The National Cancer Institute (NCI) — for cancer classification, staging conventions, and treatment nomenclature.
2. The American Society of Clinical Oncology (ASCO) — for clinical guideline citations, particularly in chemotherapy, immunotherapy, and survivorship protocols.
3. The U.S. Food and Drug Administration (FDA) — for drug approval status, biosimilar classification, and oncology device regulation under 21 CFR parts 312 and 600.

Topics originating outside U.S. jurisdiction — such as drug approvals from the European Medicines Agency (EMA) or clinical trials registered exclusively under non-U.S. frameworks — are addressed only where they intersect with FDA-regulated practice or NCI-recognized standard-of-care protocols.

The resource does not function as a clinical directory, does not maintain lists of treating physicians, and does not provide localized hospital referral services. Those functions fall within the scope of resources such as the NCI's Cancer Information Service (1-800-4-CANCER) or the ASCO's oncologist finder tool at Cancer.Net.

What to include in your message

A well-structured message reduces handling time and increases the likelihood of a substantive response. The following breakdown describes what each inquiry type should contain:

Editorial or factual correction requests
- The full URL of the page in question
- The specific sentence or statistic being disputed
- The named public source that contradicts or supersedes the current content (e.g., a specific NCI Physician Data Query [PDQ] document, an ASCO guideline version number, or an FDA label revision date)
- A brief description of the nature of the discrepancy (outdated information, misattributed statistic, incorrect regulatory citation)

Source attribution inquiries
- The claim or figure at issue
- The named agency or body expected to be the authoritative source
- The approximate section or heading where the claim appears

Accessibility or format requests
- The page or pages involved
- The specific accessibility barrier encountered (e.g., screen-reader incompatibility, color contrast issue)
- The assistive technology or format preference, where known

General subject inquiries
- A specific subject-matter question tied to a named topic (e.g., cancer staging and grading, molecular profiling and biomarkers, or clinical trials)
- Relevant context about the nature of the inquiry (research, education, professional, general public)

Messages that omit the page URL or do not identify a specific claim require a clarification exchange before review can begin, adding at least one additional response cycle.

Response expectations

Editorial and factual correction inquiries are reviewed in the order received. The standard review cycle for a correction request that includes a named source citation is 5 to 10 business days. Corrections that require cross-referencing against a primary regulatory document — such as an FDA label update or an NCI PDQ revision — may require up to 15 business days if the source document requires locating within a versioned archive.

Accessibility requests are prioritized under the HHS digital communication standards referenced above and are typically acknowledged within 3 business days regardless of resolution timeline.

General subject inquiries receive a response only where the question addresses a gap or ambiguity in existing published content. Oncology Authority does not provide individualized medical guidance, diagnostic interpretation, or treatment recommendations — functions that fall under the scope of licensed clinical professionals governed by state medical licensing boards and the standards of the American Board of Medical Specialties (ABMS). For clinical questions, the NCI Cancer Information Service at 1-800-4-CANCER provides trained health information specialists at no cost.

Messages submitted without a subject category or page reference are sorted into a general queue with a review window of up to 20 business days. Structuring the message according to the categories above routes it to the correct specialist queue and compresses that window accordingly.

Privacy Policy

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)